INHIBRX BIOSCIENCES, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $58.1M | $273.9M |
| FY2023 | $207.0M | $43.5M | $277.9M |
| FY2024 | $0 | $133.6M | $152.6M |
| FY2025 | $100.6M | $8.0M | $124.2M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $58.1M | $273.9M |
| FY2023 | $207.0M | $43.5M | $277.9M |
| FY2024 | $0 | $133.6M | $152.6M |
| FY2025 | $100.6M | $8.0M | $124.2M |